Summary of the Scientific Presentation

Click here to view a preview of the presentation.

Do you transfuse banked blood products?

By attending this seminar you'll appreciate how over 90% of all adverse reactions to transfusions, in terms of their frequency of occurrence, are mediated by leukocytes and how filtration can mitigate most of them.


Do you employ prescribe, prepare or deliver autotransfusion blood products?

Hear about the levels of fat globules, activated leukocytes and debris that are present in this "safe" blood product that could compromise pulmonary function in your patients. And see how filtration can reduce this risk.


Do you support or perform cardiac surgery?

Learn about the most recent data comparing 4 of the most popular anti-inflammatory interventions on the market today. Learn about the recent prospective randomized trial results showing Total Leukocyte Control (TLC foropen heart patients by filtration can effect a 20% reduction in hospital length of stay while reducing patient charges by $6,000.


Why You Should Attend this Seminar.

This 50 minute seminar on the topic includes review of the seminal literature covering:
  • Immunosuppression and post-op infections attributable to transfusion of the white cells that contaminate allogeneic component blood products.
  • Neutrophil-mediated reperfusion injury leading to post-pump pulmonary dysfunction following CPB and compromised myocardial preservation that may develop with intermittent blood cardioplegia administration.

You'll the framework necessary to appreciate new approaches to the applicationof TLC using Pall leukocyte reducing filtration technology. These new approaches include:

  • Strategic Leukocyte Reduction which is a manner of use of our existing arterial line leukoreducing filters to capitalize upon timing the onset of reperfusion to the pulmonary vasculature at the end of surgery with the peak leukoreductive effect of commercially available arterial line filters.
  • Delineation of leukocyte-mediated pulmonary dysfunction attributed to the high burden of leukocytes that contaminate intra-operatively salvaged blood that is concentrated, washed and ultimately reinfused.


Four Things Attendees Can Be Expected to Learn:

  • What constitutes Total Leukocyte Control and how to implement it.
  • Allogeneic leukocytes mediate adverse effects, like immunosuppression and cytomegalovirus transmission, that differ from reperfusion injury attributable to activated neutrophils (either autologous or allogeneic).
  • Reasons why neutrophil-mediated component of reperfusion injury may lead to compromised myocardial preservation and post-pump pulmonary dysfunction.
  • How the 3 most costly complications of open heart surgery, infections, respiratory failure and ventricular dysfunction, may be abrogated, in a cost-effective manner, by the program of treatment referred to as TLC.


Who Should Attend:

  • Cardiac surgeons
  • Anesthesiologists
  • Perfusionists
  • Pulmonologists/intensivists or other respiratory care professionals
  • PAs and ICU nurses
  • And anyone else involved with or concerned about cardiovascular procedures


Suggested reading:

Ortolano GA: Potential for reduction in morbidity and cost with total leukocyte control for cardiac surgery. Perfusion 10:283-290, 1995

Allen S: The role of leukocytes in the systemic inflammatory response and the potential impact of leukocyte depletion. Cardiovascular Engineering 2(1):34-54, 1997

Pertilla J, et al: Leukocyte content on blood processed by autotransfusion devices during open heart surgery. Acta Anaesthesiologica Scandinavica 39:445-448, 1995

Gu YJ, et al: Leukocyte depletion results in improved lung function and reduced inflammatory response after cardiac surgery. J Thorac and Cardiovasc Surg. 112:494-500, 1996.

Schedule a scientific presentation here!